CompletedPhase 2NCT02676349
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Studying PANDAS
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut de Cancérologie de Lorraine
- Principal Investigator
- Thierry CONROY, PrInstitut de Cancérologie de Lorraine
- Intervention
- mFolfirinox(drug)
- Enrollment
- 130 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2016 – 2025
Study locations (26)
- Institut Bergonié, Bordeaux, France
- Polyclinique Bordeaux Nord, Bordeaux, France
- Hôpital Beaujon, Clichy, France
- Chu Colmar, Colmar, France
- Hôpital Henri Mondor (APHP), Créteil, France
- Centre Oscar Lambret, Lille, France
- Chru Lille, Lille, France
- Infirmerie Protestante de Lyon, Lyon, France
- Hôpital Européen Marseille, Marseille, France
- Hôpital La Timone, Marseille, France
- Institut Paoli CALMETTES, Marseille, France
- Institut du Cancer de Montpellier, Montpellier, France
- Chu Nantes, Nantes, France
- Hôpital Cochin (APHP), Paris, France
- Institut Mutualiste Montsouris, Paris, France
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02676349 on ClinicalTrials.govOther trials for PANDAS
Additional recruiting or active studies for the same condition.